Targeting delivery in Parkinson's disease

•Neuroprotective therapies remain an unmet need for Parkinson's disease.•Targeting may allow delivery of neuroprotective molecules to the diseased brain.•This has many challenges and opportunities for the therapy of Parkinson's disease. Disease-modifying therapies for Parkinson's dise...

Full description

Saved in:
Bibliographic Details
Published in:Drug discovery today 2016-08, Vol.21 (8), p.1313-1320
Main Authors: Newland, Ben, Dunnett, Stephen B., Dowd, Eilís
Format: Article
Language:English
Subjects:
Animals
Cell- and Tissue-Based Therapy
Drug Delivery Systems
Humans
Neuroprotective Agents - administration & dosage
Parkinson Disease - therapy
Stereotaxic Techniques
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Neuroprotective therapies remain an unmet need for Parkinson's disease.•Targeting may allow delivery of neuroprotective molecules to the diseased brain.•This has many challenges and opportunities for the therapy of Parkinson's disease. Disease-modifying therapies for Parkinson's disease (PD), with the potential to halt the neurodegenerative process and to stimulate the protection, repair, and regeneration of dopaminergic neurons, remain a vital but unmet clinical need. Targeting the delivery of current and new therapeutics directly to the diseased brain region (in particular the nigrostriatal pathway) could result in greater improvements in the motor functions that characterise PD. Here, we highlight some of the opportunities and challenges facing the development of the next generation of therapies for patients with PD.
ISSN:1359-6446
1878-5832
DOI:10.1016/j.drudis.2016.06.003